Clinical Trials

42 enrolled

Malignant Solid Tumor

NCT06994806 2026-03-03

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

84 enrolled

Solid Tumor Malignancies

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

366 enrolled

Advanced Solid Tumors

NCT07204340 2026-02-27

TLN-372 in Advanced KRAS Mutant Solid Tumors

240 enrolled

KRAS Mutant Solid Tumors

NCT04219254 2026-02-25

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

197 enrolled

Phase 2 Not yet recruiting

Solid Tumor, Adult

NCT07415031 2026-02-17

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Solid Tumors

NCT05067283 2026-02-12

KANDLELIT-001

830 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumors

NCT03917381 2026-02-11

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

429 enrolled

Solid Tumors

NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

98 enrolled

Advanced Solid Tumours

NCT06480552 2026-02-05

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

240 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumors

NCT04166734 2026-02-04

MESO-PRIME

Phase 1 Terminated

5 enrolled 13 charts

Mesothelioma

NCT07182591 2026-02-03

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT07215637 2026-02-02

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

60 enrolled

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Advanced Solid Tumors

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT02856425 2026-01-20

PEMBIB

Phase 1 Completed

196 enrolled

GastrointestinalOther solid neoplasm

Patients With Any Advanced Solid Tumors

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

1 enrolled

MSI-H Colorectal Cancer

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Advanced Solid Tumor

NCT07231458 2026-01-16

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

27 enrolled

Advanced Solid Tumors

NCT05174585 2026-01-06

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

21 enrolled

Solid Tumor

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

126 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

NCT06391775 2025-12-26

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

Phase 1/2 Terminated

21 enrolled

Malignant Solid Tumor

NCT05307874 2025-12-24

EVICTION-2

Phase 1/2 Completed

56 enrolled

Solid Tumor, Adult

NCT06328673 2025-12-24

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

160 enrolled

Advanced Solid Tumor

NCT06724016 2025-12-17

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

292 enrolled

Advanced or Metastatic Solid Tumors

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

GastrointestinalHead & NeckOther solid neoplasmThoracic

242 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Head and Neck Neoplasms, Laryngeal Diseases, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Salivary Gland Neoplasms, Tracheal Diseases, Small Cell Lung Carcinoma

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

161 enrolled 44 charts

Advanced or Metastatic Solid Tumors

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

192 enrolled

Solid Tumor Malignancies

NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Other solid neoplasmThoracic

20 enrolled

Mesothelioma, Malignant

NCT05547321 2025-11-25

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

150 enrolled

Advanced Solid Tumor

NCT07095868 2025-11-21

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

94 enrolled

Selected Types of Solid Tumor

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

68 enrolled

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

110 enrolled

Advanced Solid Cancer

NCT05732831 2025-11-14

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT05859464 2025-10-20

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

34 enrolled

Malignant Solid Tumor

NCT06576037 2025-10-15

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

128 enrolled

Phase 2 Active not recruiting

Solid Tumor

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

240 enrolled

Phase 1/2 Active not recruiting

Solid Tumor

NCT02414269 2025-10-08

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

113 enrolled

BreastOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis

NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Phase 2 Terminated

106 enrolled 21 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

65 enrolled